Dr Gong on the EMBARK Trial Investigating Enzalutamide in nm

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Related Keywords

Jun Gong , Urologic Oncology Program , Samuel Oschin Comprehensive Cancer Institute , Pancreatic Cancer Research Group , Gastrointestinal Disease Research Group , Colorectal Cancer , Cedars Sinai Cancer , Prostate Cancer , Onclive Tv , Embark , Enzalutamide , Nmcspc ,